BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations - Wikidata - wikimedia - TriplyDB

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

http://www.wikidata.org/entity/Q28756824

about

sameAs

Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells Targeting the PI3K signaling pathway in cancer Regulation of Bim in Health and Disease The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives Review of the current targeted therapies for non-small-cell lung cancer Apoptotic agents Signaling cross-talk in the resistance to HER family receptor targeted therapy Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.The deubiquitinase Usp27x stabilizes the BH3-only protein Bim and enhances apoptosis Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor Neonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunction The intersection between DNA damage response and cell death pathways microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.High BIM mRNA levels are associated with longer survival in advanced gastric cancer Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim.Oncogenic mutations in intestinal adenomas regulate Bim-mediated apoptosis induced by TGF-β Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.

P2860

Q24603941-B1AC461C-F5D1-4461-9E11-F01EB961C4E9 Q24647554-B388F99E-53B1-4DE5-9517-9AB886B1FD6E Q26781203-05CE393C-125D-4DF0-A91E-647A6DB42F7D Q26851645-90BEE746-CECB-4D86-A4C5-9096F21281EB Q27010154-1716C629-714D-48C6-8789-F62DAC96C7F4 Q27014117-A3B5CBFE-A8E9-44B2-A503-E297376A3113 Q27015079-3485B84C-45A6-4358-8058-FD29842B3919 Q27016160-615EF5B8-084B-4E54-888D-DC12A8812766 Q27027778-917809F1-5698-47D1-B3A5-09AA3CB2C9C0 Q27680966-1FA4B4FE-F641-439C-B097-00A0559BE866 Q27851710-31C11D24-0CCB-460A-BA08-455217BEDC8B Q27851729-7BEFDFB9-AF59-4ADE-8422-EFCB5854279F Q27851896-00840F31-9CC7-4AE0-9A10-5218663EF420 Q27852116-B4E6EF8E-CA9A-4BE1-9916-B9141620DE66 Q27853236-1CA4EFFA-F29C-4DE3-A282-CA88DD42119C Q27853317-CA216C61-A079-46EC-BAEB-5D659261BC8D Q27853391-AF6F6C3D-880D-41D8-BA17-970583F28D5C Q28115594-11897740-A962-4858-912B-A21E4A377D20 Q28303498-93F06CAA-9E9D-4DA1-B2EA-78E3F9386ADB Q28306984-DD240857-1CC6-4A7E-92DE-211C0D616C75 Q28382921-D90F03E2-88E4-4D12-B52B-822A68F0CF37 Q28477465-10891483-2BC1-451B-98EA-8C6108CCA400 Q28611423-BF34414C-F8A3-42ED-A1AE-1046D16FB341 Q30407637-2DA4E503-1F87-4746-9DAF-85DDCB7295BF Q30850656-E686592F-3E14-4F76-AED1-709924E3EDE3 Q33304557-EE623C3A-A5B5-4C3F-9DD2-81A05E023DD6 Q33538332-BCE1D787-91AB-4417-A820-FA910AB04864 Q33553528-73F3840B-79DD-40EC-8AC4-63DA2B26B67D Q33576802-8112CADE-C182-4D59-A8BC-0EB2A8C70B47 Q33598008-83903931-F181-4536-94A4-C55DC3EF3EFD Q33618246-E9994BA2-AE04-49E0-B202-8CC0A9EAA498 Q33694667-9BEA0101-D960-4476-95FC-0686DA455BF4 Q33731181-EE267EB5-2C4E-4448-B112-26AB75CFFBD7 Q33757134-DD353CD3-FEDA-4BE9-8613-E4AA7DA590B1 Q33776876-1ED7B7BF-4D30-4095-8010-56F679013179 Q33788708-4C125CA9-5599-44A6-84A4-0891BBFF80B6 Q33825096-43D3FE40-13F1-4FFC-BA09-2DCE78A83726 Q33857728-1E0ABE60-C1D9-4ADF-89A4-A0600B7848FF Q33911863-10CE7346-6CEE-47E6-8289-20F7093E67D0 Q33938441-21A84EEC-BA94-4430-A605-10BFB9AE7E42

P2860

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

http://www.wikidata.org/entity/Q28756824

description

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 2007

@ast

scientific article (publication date: October 2007)

@en

vedecký článok (publikovaný 2007-10)

@sk

vědecký článek publikovaný v roce 2007

@cs

wetenschappelijk artikel (gepubliceerd in 2007-10)

@nl

wissenschaftlicher Artikel

@de

наукова стаття, опублікована в жовтні 2007

@uk

مقالة علمية (نشرت في أكتوبر 2007)

@ar

name

BIM mediates EGFR tyrosine kin ...... with oncogenic EGFR mutations

@ast

BIM mediates EGFR tyrosine kin ...... with oncogenic EGFR mutations

@en

BIM mediates EGFR tyrosine kin ...... with oncogenic EGFR mutations

@nl

type

label

BIM mediates EGFR tyrosine kin ...... with oncogenic EGFR mutations

@ast

BIM mediates EGFR tyrosine kin ...... with oncogenic EGFR mutations

@en

BIM mediates EGFR tyrosine kin ...... with oncogenic EGFR mutations

@nl

prefLabel

BIM mediates EGFR tyrosine kin ...... with oncogenic EGFR mutations

@ast

BIM mediates EGFR tyrosine kin ...... with oncogenic EGFR mutations

@en

BIM mediates EGFR tyrosine kin ...... with oncogenic EGFR mutations

@nl

P1433

Q28756824-1D5A599A-96E0-401E-A2C7-A17250DB5E4C

P1476

Q28756824-6614B943-98E6-4ACA-9EB2-1898A39020F3

P2093

Q28756824-3CDE2D66-B476-4195-8BC1-595309A3E162

Q28756824-7C2E1034-BB29-4F3D-B82B-540386A3F7B0

Q28756824-8B30813A-BC65-4739-AFC8-2CEDDE6C0BA4

Q28756824-B16C3674-0973-47CB-B1AD-74B13CA14B47

Q28756824-BFC39E5F-EFD4-40BF-8B48-94CB040CFA9A

Q28756824-C4D24A2F-04E6-4F22-B934-55D298E0B975

Q28756824-DE1A4B4C-25FC-441B-8C35-3DBFE24694C1

Q28756824-E3390B19-70AB-45AA-97DD-3A7AF89E2A17

P2860

Q28756824-025B5038-CB43-43C2-8B5F-E29003DA6F24

Q28756824-02E9B805-26D9-4916-A066-DC750FA92D93

Q28756824-08749658-2BA1-4D9E-82F3-BB8F722773AE

Q28756824-0CA8F15D-90BB-439C-95BD-41E44531D22C

Q28756824-13C7EF20-6210-4666-A217-9A77090105A5

Q28756824-160C4C9D-EB80-4A6B-8B89-5C132E8DC83F

Q28756824-16F8973B-D1B8-4919-A255-891736818439

Q28756824-1A04FA0E-32C4-4554-BB86-00F9EBBFBF56

Q28756824-1F0F2581-57A1-4C24-8BDB-523C7B7C1292

Q28756824-240C1336-8F33-4E1F-AE6C-84D12FCAB738

P304

Q28756824-B7FE24B6-E4BE-4CEC-89E8-1C965334129C

P31

Q28756824-53E83805-B622-4B9A-98BB-D434DF311ADD

P3181

Q28756824-36BC66A2-EBA4-428A-9CEF-2CB34F175458

P356

Q28756824-CF693F3E-1B84-40A9-8F5C-30F1FE9548E0

P407

Q28756824-B0C1DC86-38FB-44F9-BF2C-335F6D4D749F

P433

Q28756824-CE222A89-3B25-4102-8A38-940337E072AE

P478

Q28756824-917E5FA0-90B3-47AB-B7E3-2A77DD5AF9CA

P577

Q28756824-5F7BC3D9-F534-4E1A-A2E6-84B175500681

P5875

Q28756824-DF8C6706-DF10-4996-BED2-B9D77951AE70

P698

Q28756824-A061A143-26D0-43DA-A20F-2A9A7218E4F8

P921

Q28756824-8DE9BA3D-5D8E-4657-8C57-75260FDA252F

P932

Q28756824-86232631-CCE6-48DE-A522-AF310E426E39

P3181

P356

JOURNAL.PMED.0040315

P1433

P1476

BIM mediates EGFR tyrosine kin ...... with oncogenic EGFR mutations

@en

P2093

Amit Kumar

http://www.w3.org/2001/XMLSchema#string

Balázs Halmos

http://www.w3.org/2001/XMLSchema#string

Daniel B Costa

http://www.w3.org/2001/XMLSchema#string

Daniel G Tenen

http://www.w3.org/2001/XMLSchema#string

Mark S Huberman

http://www.w3.org/2001/XMLSchema#string

Susan T Schumer

http://www.w3.org/2001/XMLSchema#string

Susumu Kobayashi

http://www.w3.org/2001/XMLSchema#string

Titus J Boggon

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

P304

1669-79; discussion 1680

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3376042

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.0040315

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5871948

http://www.w3.org/2001/XMLSchema#string

P698

17973572

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

2043012

http://www.w3.org/2001/XMLSchema#string